Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense, Eversense XL, and Eversense E3 which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics Holdings, Inc.

DexCom DXCM delivered robust first-quarter 2025 results, underpinned by strong category demand, record new patient growth and meaningful progress in its long-term strategic initiatives. As the year progresses, several key growth drivers are set to propel the business forward, even as the company faces operational and regulatory headwinds. Dexcom’s strong commercial execution, expanding access footprint and pipeline innovation position it well for long-term growth. Yet, execution in logistics, regulatory compliance, and payer strategy will be critical for converting these tailwinds into sustainable margin expansion.
This Zacks Rank #3 (Hold) company’s shares have gained 18.6% quarter to date compared to the industry’s 4.5% decline. The S&P 500 Index has improved 6.9% in the same time frame.
DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $31.76 billion. It projects a 23.1% growth rate over the next five years and anticipates maintaining a strong performance going forward.
Image Source: Zacks Investment Research
DexCom’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed twice, the average surprise being 0.47%.
Access Gain and Market Penetration
A major inflection point for Dexcom in 2025 is the significant expansion in reimbursement coverage for people with type 2 diabetes (T2D), particularly those who are not on insulin. As of summer 2025, Dexcom’s G7 continuous glucose monitor (CGM) will be covered by all three major pharmacy benefit managers (PBMs) for anyone with diabetes, unlocking access for nearly 6 million non-insulin users. Encouragingly, the first quarter already saw a material increase in new starts from this cohort, the highest in Dexcom’s history. Physician prescribing patterns are shifting in tandem with these policy changes, setting the stage for accelerating patient adoption in the back half of the year.
Simultaneously, Dexcom’s over-the-counter CGM, Stelo, is helping capture a broader audience, including patients with prediabetes and those interested in wellness and metabolic health. The company has rolled out app enhancements, launched on Amazon, and observed a rising subscription trend among early adopters. While still in early stages, Stelo adds a consumer-facing channel that complements the prescription-based G7 ecosystem.
Image Source: dexcom.com
Innovation and Commercial Execution
The upcoming launch of the 15-Day G7 system marks a technological leap for Dexcom. With improved accuracy (MARD of 8.0%) and extended wear time, the device is expected to bolster gross margins and deepen product differentiation. Integration efforts with insulin pump partners and payer contracting are already underway to ensure a seamless rollout in the second half of 2025.
Additionally, Dexcom continues to benefit from operational leverage. Following a major sales force expansion in 2024, the company is now optimizing reach and productivity, especially in the basal and primary care segments. Internationally, momentum is building in markets like France and Japan, aided by Dexcom ONE’s growing presence and type 2 coverage wins.
Dexcom’s $2.7 billion cash position and the announcement of a $750 million share buyback reflect strong balance sheet health and confidence in long-term cash flow generation. Despite inflation and logistics cost headwinds, the company reaffirmed its full-year revenue and EBITDA margin guidance, highlighting effective cost control and prioritization.
Estimate Trend
DexCom has witnessed a stable estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for 2025 earnings per share has remained stable at $2.03.
Image Source: Zacks Investment Research
The consensus mark for the company’s second-quarter revenues is pegged at $1.12 billion, indicating an 11.8% improvement from the year-ago quarter’s reported number. The consensus estimate for earnings is pinned at 45 cents per share, implying an improvement of 4.7% year over year.
Image Source: Zacks Investment Research
Navigating Near-Term Challenges
However, Dexcom is not without headwinds. Gross margin guidance for fiscal 2025 was revised down to nearly 62%, primarily due to supply-chain disruptions that began in late 2024. To maintain customer continuity, Dexcom resorted to costly chartered flights and now faces a prolonged inventory rebuild. These freight-related expenses, combined with nearly 50 bps of inflation from raw material tariffs and FX volatility, are expected to weigh on profitability through the third quarter.
Separately, Dexcom is addressing a warning letter from the FDA tied to 2024 inspections. While it does not restrict product approvals or sales, it demands ongoing resource allocation and operational focus. The company is cooperating with the agency and has begun implementing corrective measures.
Lastly, while Dexcom is advocating Medicare coverage for non-insulin T2D users, progress hinges on a randomized controlled trial set to report results in late 2025 or early 2026. A favorable outcome could unlock another major addressable market.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
CGM Competition on the Rise
While Dexcom leads in sensor accuracy and access, its three listed rivals — Abbott Laboratories ABT, Medtronic MDT and Senseonics SENS — are rapidly innovating, creating a more competitive and segmented CGM market landscape in 2025 and beyond.
Abbott Laboratories continues to expand its CGM footprint with its FreeStyle Libre family and the recent launch of Libre Rio, an FDA-cleared OTC device targeting insulin-free Type 2 diabetes patients. Abbott Laboratories’ broad portfolio and consumer wellness push with Lingo directly challenge Dexcom’s Stelo strategy, especially in the growing OTC and metabolic health market.
Medtronic, while spinning off its diabetes unit, remains a strong force through its MiniMed 780G system. Its integration of CGM with insulin pumps competes directly with Dexcom’s G7-enabled automated delivery partnerships. The forthcoming spin-off could streamline Medtronic’s focus and reinvigorate innovation.
Senseonics, although smaller in scale, presents a differentiated offering with its implantable Eversense CGM. With sensor wear times of up to 365 days, it appeals to a niche segment prioritizing convenience and minimal maintenance, pressuring Dexcom to enhance G7’s longevity and user comfort. As adoption grows, Senseonics’ Eversense could influence payer and clinician preference dynamics, particularly among high-adherence, low-maintenance patient cohorts.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Senseonics Holdings, Inc. (SENS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

DXCM's Access Gains and Operational Strength Offset Margin Pressures

(RTTNews) - Shares of Senseonics Holdings, Inc. (SENS) are down 13.33% in premarket trading Tuesday, following the company's financial results for the fourth quarter and full year ended December 31, 2024.
For the fourth quarter of 2024, Senseonics generated $8.3 million in revenue, slightly up from $8.0 million in the fourth quarter of 2023, driven by the launch of its Eversense 365 continuous glucose monitoring (CGM) system.
The net loss for the fourth quarter of 2024 was $15.5 million, or $0.02 per share, compared to a net loss of $17.2 million, or $0.03 per share, in the same period in 2023. The improved net loss was primarily attributed to better margins on the 365-day product.
The company's revenue for the full year of 2024 was relatively flat at $22.47 million compared to $22.39 million in 2023.
For the Full Year of 2024, the company reported a wider net loss of $78.62 million, or $0.12 per share, compared to a net loss of $69.39 million, or $0.11 per share, in 2023.
The company also announced that its Eversense 365 CGM, approved and launched in the U.S. in 2024, is showing promising performance.
In December 2024, the company achieved its highest monthly total in history, with approximately 600 new patient shipments. Additionally, in 2024, the company surpassed 2,400 annual U.S. Eversense prescribers, the majority of whom were new to prescribing the product.
The company's global patient base grew 56 percent in 2024, reaching approximately 6,000 patients.
Looking ahead to 2025, Senseonics expects its total revenue to be between $34 million and $38 million, driven by the continued rollout of Eversense 365. The total revenue was $22.47 million in 2024.
The company expects to double its global patient base in 2025, with gross margins projected to improve throughout the year to between 25 and 30 percent.
As of December 31, 2024, Senseonics had $74.9 million in cash, cash equivalents, and restricted cash, with $56.2 million in outstanding indebtedness.
SENS closed Monday's (Mar.03 2025) trading at $0.87, up by 2.35 percent. In premarket trading Tuesday, the stock is down by 13.33 percent at $0.75 on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Senseonics Expects 2025 Revenue To Rise By 51% To 69%

(RTTNews) - Senseonics Holdings, Inc. (SENS) a medical technology company has announced the completion of its CE Mark submission for the Eversense 365 Continuous Glucose Monitoring or CGM system, the world's first and only one-year CGM. The Eversense 365 system, approved by the U.S. FDA in September 2024 and launched in October 2024, is now one step closer to being available in the European Union or EU.
The submission, prepared under the EU Medical Device Regulation or MDR, will allow the commercialization of the system in several EU countries through Senseonics' commercial partner, Ascensia Diabetes Care.
The system is expected to be available in Germany, Italy, Spain, Poland, Switzerland, and Sweden following CE Mark approval.
Key Highlights:
-- Eversense 365 offers the longest-lasting CGM, staying active for an entire year, a significant improvement over traditional 10-14-day CGMs.
-- Benefits include consistent accuracy, minimal false alerts, and the ability to integrate with insulin pumps for automated insulin delivery systems.
Senseonics is optimistic about the future impact of Eversense 365 in Europe, building on its U.S. launch success and positive feedback from patients and healthcare providers.
The company plans to expand the availability of the system after CE Mark approval, aiming to enhance glucose control for people with diabetes across Europe.
Currently, SENS is trading at $1.00 up by 8.84%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Senseonics Completes CE Mark Submission For Eversense 365 CGM System

Senseonics Holdings, Inc. SENS, along with Ascensia Diabetes Care, announced the receipt of the FDA’s clearance for the next-generation Eversense 365 continuous glucose monitoring (CGM) system for people with Type 1 and Type 2 diabetes aged 18 years and above. Eversense 365 has been cleared as an integrated CGM (iCGM) system, indicating that it can integrate with compatible medical devices, including insulin pumps, as part of an automated insulin delivery system.
Ascensia, a subsidiary of PHC Holdings Corporation, expects to initiate the U.S. launch of Eversense 365 U.S. in the fourth quarter of 2024, with work ongoing to transition coverage availability to facilitate immediate access to as many users as possible.
The latest FDA clearance of Senseonics’ Eversense 365 is expected to significantly solidify its foothold in the CGM business across the nation.
Likely Trend of SENS Stock Following the News
Following the announcement on Sept. 17, 2024, shares of the company moved nearly 20% south to $0.35 at yesterday’s close.
Historically, the company has gained a high level of synergies from its partnerships and regulatory clearances. Although the latest regulatory clearance is likely to be beneficial for SENS’ top-line growth going forward, the stock plunged as it continued its week-long downtrend.
Meanwhile, Senseonics currently has a market capitalization of $186.3 million. It has a current ratio of 3.1, higher than the industry’s 2.3. In the last reported quarter, SENS delivered a breakeven earnings surprise.
Significance of Approval of Senseonics’ iCGM System
Per Senseonics, Eversense 365 is the world’s first One-Year CGM system, representing a significant breakthrough in diabetes technology and management. With a single sensor, the Eversense 365 system is expected to provide one year of use compared with 10-14 days with short-term CGMs for minimal life disruption.
Senseonics’ management believes that the Eversense 365 is optimally suited to aid diabetics increase time in range of desired glucose levels and lower A1c levels.
Industry Prospects in Favor of SENS’
Per a report by Grand View Research, the global CGM device market size was valued at $4.60 billion in 2023 and is expected to reach $7.51 billion by 2030 at a CAGR of approximately 7.2%. Factors like the rising cases of diabetes and the increasing adoption of CGM devices are likely to drive the market.
Given the market potential, the latest regulatory approval is expected to provide a significant boost to Senseonics’ business.
Senseonics’ Notable Developments
Last month, Senseonics reported its second-quarter 2024 results, wherein it registered a solid uptick in its revenues. During the quarter, the company began first-in-human testing for the Gemini System, a fully implantable self-powering system designed to include a flash glucose monitor with no on-body component for people with type 2 diabetes.
In May, Senseonics, in partnership with our global commercial partner, Ascensia Diabetes Care, and St. Louis-based Mercy, announced a collaboration that marks the first time Senseonics’ Eversense CGM technology will be used across a health system and the first implementation of Senseonics’ new Eversense Remote Patient Monitoring (RPM) solution to drive significant advancement in diabetes management for patients.
The same month, Senseonics announced a strategic partnership with Rimidi for the development of its Eversense RPM Program for use by healthcare providers. The partnership will integrate Eversense glucose data into Rimidi's comprehensive clinical management platform used by health systems, capitated health plans and physician practices.
SENS’ Share Price Performance
Shares of the company have lost 33.2% in the past year against the industry’s 6.7% rise and the S&P 500's 31.5% growth.
Image Source: Zacks Investment Research
Senseonics’ Zacks Rank & Stocks to Consider
Currently, SENS carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are DaVita Inc. DVA, Baxter International Inc. BAX and Boston Scientific Corporation BSX.
DaVita, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 17.5%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 62.8% compared with the industry’s 31.1% rise in the past year.
Baxter, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 10%. BAX’s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.7%.
Baxter has gained 4.3% compared with the industry’s 22.1% rise in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.2%.
Boston Scientific’s shares have rallied 55% compared with the industry’s 22.1% rise in the past year.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Baxter International Inc. (BAX) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Senseonics Holdings, Inc. (SENS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Senseonics Stock Down Despite New FDA Approval for Eversense 365

Clover Health Investments, Corp. (CLOV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 28.57%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.12, delivering a surprise of 33.33%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Clover Health Investments, which belongs to the Zacks Medical Info Systems industry, posted revenues of $346.92 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 9.75%. This compares to year-ago revenues of $527.78 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Clover Health Investments shares have lost about 24.4% since the beginning of the year versus the S&P 500's gain of 8.6%.
What's Next for Clover Health Investments?
While Clover Health Investments has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Clover Health Investments: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $315 million in revenues for the coming quarter and -$0.20 on $1.25 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Senseonics Holdings (SENS), has yet to report results for the quarter ended March 2024. The results are expected to be released on May 13.
This medical technology company is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Senseonics Holdings' revenues are expected to be $4.76 million, up 14.9% from the year-ago quarter.
Where Will Stocks Go…
If Biden Wins? If Trump Wins?
The answers may surprise you.
Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!
Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…
1. Medical manufacturer has gained +11,000% in the last 15 years.
2. Rental company is absolutely crushing its sector.
3. Energy powerhouse plans to grow its already large dividend by 25%.
4. Aerospace and defense standout just landed a potentially $80 billion contract.
5. Giant Chipmaker is building huge plants in the U.S.
Hurry, Download Special Report FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.